Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 645 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Niacin Clear all
Terminated Phase 2 Interventional Results available

Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas

NCT01338857
View directory record Official record
Conditions
neurofibromatosis1 (NF1), Recurrent or Progressive Optic Pathway Gliomas (OPG), Recurrent or Progressive Low-grade Glioma
Interventions
Sorafenib (Nexavar)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
2 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 17, 2026, 4:47 PM EDT
Completed Not applicable Interventional

A Pilot Clinical Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy.

NCT00605930
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
Pyruvate, creatine, niacinamide, Placebo
Dietary Supplement
Lead sponsor
University of Louisville
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 17, 2026, 4:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

"Pharmacokinetic Study of Nicotinamide Riboside"

NCT02689882
View directory record Official record
Conditions
Metabolic Disturbance
Interventions
nicotinamide riboside
Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Oct 17, 2026, 4:47 PM EDT
Withdrawn Phase 2 Interventional

Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC

NCT02406508
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
Melphalan/HDS, Sorafenib
Device · Drug
Lead sponsor
Delcath Systems Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Tampa, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Oct 17, 2026, 4:47 PM EDT
Completed Phase 1 Interventional

Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant

NCT00844168
View directory record Official record
Conditions
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions
sorafenib tosylate, laboratory biomarker analysis
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 27, 2015 · Synced Oct 17, 2026, 4:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety and Tolerability of a Novel Amino-acid Based Hydration Drink in Healthy Volunteers

NCT05592951
View directory record Official record
Conditions
Safety, Tolerance
Interventions
Crystal Light (once serving), Liquid IV with amino acids (one serving), Liquid IV with amino acids (two servings), Liquid IV with amino acids (three servings)
Dietary Supplement
Lead sponsor
University of Memphis
Other
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 17, 2026, 4:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer

NCT00126503
View directory record Official record
Conditions
Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Interventions
Bevacizumab, Sorafenib Tosylate, Pharmacological Study, Laboratory Biomarker Analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
5
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Oct 17, 2026, 4:47 PM EDT
Completed Phase 1 Interventional Results available

Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.

NCT03356483
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Psilocybin (0.25mg/kg), Niacin (250mg)
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 4:47 PM EDT
Recruiting Not applicable Interventional

Mechanistic Study of Nicotinamide Riboside on NAD+ Biology in Individuals With Combined Pulmonary Hypertension

NCT07563322
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Nicotinamide Riboside (NR), Placebo
Dietary Supplement · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 17, 2026, 4:47 PM EDT
Recruiting Phase 2 Interventional

Matching Perfusion and Metabolic Activity in HFpEF

NCT04913805
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Potassium Nitrate, Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside, Potassium Chloride
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 17, 2026, 4:47 PM EDT
Completed Phase 2 Interventional

Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

NCT00095966
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
sorafenib tosylate, gemcitabine hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Oct 17, 2026, 4:47 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

The Role of Hepatic Denervation in the Dysregulation of Glucose Metabolism in Liver Transplant Recipients

NCT03685773
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Glucose, High Blood, Glucose Metabolism Disorders
Interventions
Diazoxide, Placebo (for diazoxide), Nicotinic acid
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
21 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 17, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma

NCT02576509
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Nivolumab, Sorafenib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Oct 17, 2026, 4:47 PM EDT
Completed Phase 1 Interventional

Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery

NCT01497444
View directory record Official record
Conditions
Kidney Cancer, Liver Cancer
Interventions
hypoxia-activated prodrug TH-302, sorafenib tosylate
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Oct 17, 2026, 4:47 PM EDT
Completed Phase 1 Interventional

Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma

NCT00822848
View directory record Official record
Conditions
Sarcoma
Interventions
epirubicin hydrochloride, ifosfamide, sorafenib tosylate, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, hypofractionated radiation therapy
Drug · Other · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
15 Years to 120 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 17, 2026, 4:47 PM EDT
Terminated Phase 2 Interventional Results available

Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT00726986
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, etoposide, sorafenib tosylate
Drug
Lead sponsor
Afshin Dowlati, MD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
11
States / cities
New York, New York • Cleveland, Ohio • Mayfield Heights, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Oct 17, 2026, 4:47 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

NCT02642159
View directory record Official record
Conditions
Dyslipidemia
Interventions
Alirocumab, Statins, Ezetimibe, Fenofibrate, Nicotinic acid, Omega-3 fatty acids, Antihyperglycemic Drug
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
57
States / cities
Little Rock, Arkansas • Fresno, California • Huntington Beach, California + 51 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 17, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer

NCT00881751
View directory record Official record
Conditions
Liver Cancer
Interventions
bevacizumab, erlotinib hydrochloride, sorafenib tosylate
Biological · Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 116 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 17, 2026, 4:47 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Nicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study

NCT05695027
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Dietary supplements - Nicotinamide and Pyruvate, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
35 Years to 85 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
3
States / cities
Palo Alto, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 17, 2026, 4:47 PM EDT
Completed Phase 1 Interventional

Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors

NCT00572078
View directory record Official record
Conditions
SOLID TUMORS
Interventions
Sorafenib
Drug
Lead sponsor
Safi Shahda
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 17, 2026, 4:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Niaspan on Cholesterol in Men

NCT00765284
View directory record Official record
Conditions
HDL Cholesterol
Interventions
Not listed
Lead sponsor
KineMed
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2011 · Synced Oct 17, 2026, 4:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients

NCT01561833
View directory record Official record
Conditions
T Cell Lymphoma
Interventions
Sorafenib
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Oct 17, 2026, 4:47 PM EDT
Completed Phase 1 Interventional

Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer

NCT00466232
View directory record Official record
Conditions
Small Cell Carcinoma, Lung Cancer
Interventions
Topotecan, Sorafenib
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Saint Louis Park, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 16, 2015 · Synced Oct 17, 2026, 4:47 PM EDT
Terminated Phase 1 Interventional

Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung Cancer

NCT00543335
View directory record Official record
Conditions
Lung Cancer
Interventions
Sorafenib, Radiation Therapy
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 17, 2026, 4:47 PM EDT